Antigens Rv0310c and Rv1255c Are Promising Novel Biomarkers for the Diagnosis of Mycobacterium Tuberculosis Infection
Overview
Affiliations
This study aimed to identify novel immunogenic epitopes from Mycobacterium tuberculosis (MTB) that could be used in tuberculosis (TB) diagnostics. To determine the diagnostic potential of mycobacterial antigens in serodiagnosis of TB, 256 patients were enrolled in a study and divided into two groups: 126 smear-positive pulmonary TB patients (SPPT) and 130 smear-negative pulmonary TB patients (SNPT); 152 bacillus Calmette-Guerin (BCG)-vaccinated healthy people were used as a control. Murine results showed that antigens Rv0310c-E from RD 8 and Rv1255c-E from RD 10 were strongly immunogenic to Th1 cells and induced a great humoral response. Receiver operating characteristic analysis indicated that Rv0310c-E (area under the curve (AUC): 0.800) and Rv1255c-E (AUC: 0.808) performed better than ESAT-6 (AUC: 0.665) and CFP-10 (AUC: 0.623) proteins but were comparable with Rv3425 (AUC: 0.788) protein in a human serum IgG analysis. Rv0310c-E demonstrated the highest diagnostic ability for the SPPT group (Youden index: 0.5602, sensitivity: 69.84%, specificity: 86.18%), while Rv1255c-E demonstrated the highest diagnostic ability for the SNPT group (Youden index: 0.5674, sensitivity: 73.84%, specificity: 82.89%). In addition, combination analysis found that antigen Rv0310c-E, coupled with the Rv3425 protein (Youden index: 0.6098, sensitivity: 87.30%, specificity: 73.68%) had the strongest performance for TB diagnostics of the SPPT group, and the single antigen Rv1255c-E was strongest for the SNPT group. These results suggest that antigens Rv0310c-E and Rv1255c-E are potential antigens for TB serodiagnostic tests, which may facilitate detection of MTB in smear-negative and smear-positive patients.
Antibodies as key mediators of protection against .
Wang Q, Nag D, Baldwin S, Coler R, McNamara R Front Immunol. 2024; 15:1430955.
PMID: 39286260 PMC: 11402706. DOI: 10.3389/fimmu.2024.1430955.
Li X, Zhao W, Han H, Yang Z, Bi F, He Y Saudi Med J. 2024; 45(7):658-666.
PMID: 38955446 PMC: 11237276. DOI: 10.15537/smj.2024.45.7.20240310.
Wang J, Jiang F, Cheng P, Ye Z, Li L, Yang L Mol Biomed. 2024; 5(1):15.
PMID: 38679629 PMC: 11056354. DOI: 10.1186/s43556-024-00177-z.
Antibodies as clinical tools for tuberculosis.
McIntyre S, Warner J, Rush C, Vanderven H Front Immunol. 2024; 14:1278947.
PMID: 38162666 PMC: 10755875. DOI: 10.3389/fimmu.2023.1278947.
Advancing personalized medicine for tuberculosis through the application of immune profiling.
Thu V, Dat L, Jayanti R, Trinh H, Hung T, Cho Y Front Cell Infect Microbiol. 2023; 13:1108155.
PMID: 36844400 PMC: 9950414. DOI: 10.3389/fcimb.2023.1108155.